4.8 Review

Towards a classification of biomarkers of neuropsychiatric disease: from encompass to compass

期刊

MOLECULAR PSYCHIATRY
卷 20, 期 2, 页码 152-153

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/mp.2014.139

关键词

-

资金

  1. NHMRC [1059660, 1056929]
  2. NIH
  3. Simons Autism Foundation
  4. Cancer Council of Victoria
  5. CRC for Mental Health
  6. Stanley Medical Research Foundation
  7. MBF
  8. Beyond Blue
  9. Geelong Medical Research Foundation
  10. Bristol Myers Squibb
  11. Eli Lilly
  12. GlaxoSmithKline
  13. Organon
  14. Novartis
  15. Mayne Pharma
  16. Servier
  17. Brain and Behaviour Foundation (NARSAD)
  18. Canadian Institute of Health Research
  19. State of Minnesota
  20. National Health and Medical Research Council of Australia [1056929] Funding Source: NHMRC

向作者/读者索取更多资源

There is currently considerable imprecision in the nosology of biomarkers used in the study of neuropsychiatric disease. The neuropsychiatric field lags behind others such as oncology, wherein, rather than using 'biomarker' as a blanket term for a diverse range of clinical phenomena, biomarkers have been actively classified into separate categories, including prognostic and predictive tests. A similar taxonomy is proposed for neuropsychiatric diseases in which the core biology remains relatively unknown. This paper divides potential biomarkers into those of (1) risk, (2) diagnosis/trait, (3) state or acuity, (4) stage, (5) treatment response and (6) prognosis, and provides illustrative exemplars. Of course, biomarkers rely on available technology and, as we learn more about the neurobiological correlates of neuropsychiatric disorders, we will realize that the classification of biomarkers across these six categories can change, and some markers may fit into more than one category.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据